chimeric antigen receptor T cell

BIOLOGICAL3 trials

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseAcute Myeloid LeukemiaCARPancreatic CancerRefractory Acute Lymphoid LeukemiaRefractory Acute Myeloid LeukemiaRelapse Leukemia

Early Phase 1

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

NCT03267173

First Affiliated Hospital of Harbin Medical UniversityCAR, Pancreatic Cancer

Start: 2017-06-15End: 2019-06-30Target: 10Updated: 2017-08-30

Phase 1

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT04835519

Beijing Boren HospitalAcute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapse Leukemia

Start: 2021-04-08End: 2023-05-19Updated: 2024-06-21

Phase 2

Study of Sequential CAR-T Cell Treating Leukemia Children

TerminatedNCT04340154

Beijing Boren HospitalAcute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia

Start: 2020-05-01End: 2024-11-30Updated: 2024-12-05

Blood2024-11-051 citations

C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial.

2024-07-2221 citations

Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia.

Journal of Clinical Oncology2024-06-016 citations

Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission

Blood Science2024-01-01

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.

2023-10-1738 citations

chimeric antigen receptor T cell

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2

Related Papers